•
The TPG-National Payor Roundtable (TPG-NPRT) focuses on market access programs within the United States and is a subsidiary of The Pharmacy Group. •
The JeSTARx Group provides evidence-based research and support to the Healthcare Industry. •
The TPG-NPRT maintains a proprietary database of Chief Medical Officers, Chief Pharmacy Officers and other key decision makers from health plans in the United States. • "Specialty pharmacy" products are pharmaceuticals designed to treat specific, complex chronic diseases and have four or more of the following attributes shown in Top causes of concern today, and in the future. • Expenditures for Specialty Pharmacy products and the use of specialty pharmacy will continue to grow. • The environment for P&T Committee decision making in managed care is undergoing a series of changes. • Payor medical directors and pharmacy directors, who commonly serve as P&T Committee members, have a distinct understanding and opinions as to how to alter the process to adapt to these influences.
Methods

Conclusions
Disclosures: None
Responses to open-ended questions placed Specialty Pharmacy products as the top causes for concern currently, and for the coming years.
The disease states most concerning to these plan directors from a medical care point of view: • Overall, there were differences between the benefits used for clinician-administered products (injections/infusions) and oral biologics ( Figure 5) : -Cost-thresholds were used to determine benefit type for both types of products. 
